Table 3. Correlation analysis and stepwise forward regression analysis to access the influence of each pre-treatment factor on BCVA in LogMAR at 24 Months after Initial IVB for mCNV.
| Covariate (Pre-treatment factors) |
Pearson's correlation analysis |
Stepwise forward regression analysisa |
||
|---|---|---|---|---|
| r | P-value | Standardized β | P-value | |
| CNV size | 0.56 | 0.0056 | 0.56 | 0.0056 |
| CNV location | 0.50 | 0.014 | Not included | — |
| Duration of symptoms | 0.49 | 0.019 | Not included | — |
| BCVA in logMAR | 0.39 | 0.065 | Not included | — |
| Age | 0.25 | 0.24 | Not included | — |
| Axial length | −0.22 | 0.32 | Not included | — |
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of the minimal angle of resolution; mCNV, myopic choroidal neovascularization; r, Pearson's correlation coefficient; β, regression coefficient.
a
Adjusted R2 (the coefficient of multiple determination)=0.279.